Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2013 Results
Date:9/30/2013

CRANBURY, N.J., Sept. 30, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its fourth quarter and fiscal year ended June 30, 2013. 

Fiscal Year and Recent Highlights

  • Bremelanotide development for Female Sexual Dysfunction (FSD):
  • Completed a successful Phase 2B clinical trial and productive end-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA)
  • Pivotal Phase 3 clinical trials anticipated to initiate patient dosing in the first quarter of calendar year 2014
  • Obesity Collaboration with AstraZeneca:
  • AstraZeneca is evaluating the program and next steps following discontinuation of further development of AZD2820
  • A number of collaboration compounds are in various stages of preclinical testing
  • Intellectual property developments:
  • Two United States patents issued in the melanocortin field in the fiscal year ended June 30, 2013
  • Palatin has advanced its bremelanotide, PL-3994, and new melanocortin peptide patent applications in countries outside the United States
  • Equity financing:
  • On July 3, 2012, Palatin closed on a $35.0 million private placement.  The offering consisted of the sale of 3,873,000 shares of common stock, Series A 2012 warrants to purchase 31,988,151 shares of common stock, and Series B 2012 warrants to purchase 35,488,380 shares of common stock 
  • Net proceeds to Palatin after deducting offering expenses were $34.4 million 
  • Fourth Quarter and Fiscal Year End 2013 Results
    Palatin reported a net loss of $4.7 million, or $(0.04) per basic and diluted share, for the quarter ended June 30, 2013, compared to a net loss of $5.3 million, or $(0.14) per basic and diluted sha
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Palatin Technologies Announces Last Patient Completed Treatment In Phase 2B Bremelanotide Female Sexual Dysfunction Trial
    2. Palatin Technologies Announces Notification of Patent Allowance On Melanocortin Receptor-1 Specific Peptides
    3. Palatin Technologies, Inc. To Report Fiscal Year 2013 Fourth Quarter Results
    4. U.S. Patent Office Issues Sixth Patent Covering Zero-Footprint Medical Image Viewers to Heart Imaging Technologies, LLC
    5. Lifeline Biotechnologies, Inc. Receives Patent Award, a Device for Breast Tissue Temperature Analysis for Determining Cancer Conditions
    6. Radiation Control Technologies, Inc. Announces Exclusive License to Two Patents from the National Institutes of Health
    7. CanCHEW Bio-Technologies, a Medical Marijuana Inc. Product, Dr. George Anastassov Appeared on Small Cap Voice Internet Radio Program To Discuss The CanCHEW Advantage
    8. Drug Discovery Technologies, BCC Research
    9. OrthoAccel Technologies, Inc. Announces Appointment of New Chief Financial Officer
    10. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on February 7th
    11. Novel Biomaterials Accelerate the Development of Innovative Wound Care Management Technologies, Finds Frost & Sullivan
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... 2014  Zafgen, Inc., a leading biopharmaceutical company dedicated ... patients, today announced initial results from its Phase ... methionine aminopeptidase 2 (MetAP2), in patients with Prader-Willi ...  These results showed improvements in body weight, hunger-related ...
    (Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, ... innovator of less invasive, miniaturized circulatory support technologies that ... announced that it expects revenues for the fourth quarter ... full-year 2013 revenues to approximately $208 million. ...
    (Date:1/14/2014)... North America,s leading business partnering event ... 30 th edition of its annual conference at the ... 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... specialty chemical companies will take part in the conference, which ...
    Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
    ... useful and focused trial that builds on the body ... possible care for diabetic patients with chronic stable angina ... for Cardiovascular Angiography and Interventions (SCAI) encourages healthcare providers ... their patients, as studied in this trial. BARI-2D ...
    ... 69th Annual ADA Scientific Sessions Examined Efficacy and Safety ... , NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- ... "Effects of 1, 2, or 3 Prandial Injections of ... Patients on Insulin Glargine and Oral Drugs," evaluating patients ...
    Cached Medicine Technology:SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 2SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 3SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine 4New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar 2New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar 3
    (Date:4/20/2014)... cell in the lining of the bladder is responsible ... researchers at the Stanford University School of Medicine. , ... pinpoint the normal cell type that can give rise ... show that most bladder cancers and their associated precancerous ... many human bladder cancers recur after therapy. , "We,ve ...
    (Date:4/18/2014)... prepped to enter the battle against infectious disease. ... in remote areas, thanks in part to knowledge ... International Space Station on the behavior of liquids. ... flow to diagnose infectious diseases such as HIV/AIDS ... at Northwestern University in Evanston, Ill., had been ...
    (Date:4/18/2014)... have made a discovery that turns 160 years of ... material long known to be essential for the fast ... is not as ubiquitous as thought, according to a ... Harvard Stem Cell Institute (HSCI) and the University,s Department ... Professor Jeff Lichtman, of Harvard,s Department of Molecular and ...
    (Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
    (Date:4/18/2014)... psychologists have made a brain-related discovery that could ... , This discovery opens up the possibility that ... a specific brain activity that the researchers have ... Journal of Neuroscience has just published ... an associate professor of psychology and his doctoral ...
    Breaking Medicine News(10 mins):Health News:Stanford scientists identify source of most cases of invasive bladder cancer 2Health News:Stanford scientists identify source of most cases of invasive bladder cancer 3Health News:Stanford scientists identify source of most cases of invasive bladder cancer 4Health News:Stanford scientists identify source of most cases of invasive bladder cancer 5Health News:Space-tested fluid flow concept advances infectious disease diagnoses 2Health News:Space-tested fluid flow concept advances infectious disease diagnoses 3Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2
    ... LONGVIEW, Texas, April 1 Searching for ... through a dizzying array of,options? RxPop.com ( http://www.rxpop.com ... its award-winning website to provide people with a ... facilities,nationwide., RxPop.com,s debut "Local Doctor Search",( http://www.rxpop.com/local_doctor_search.asp ...
    ... Old Fashioned Medicine with a High ... ... 2008 MedeFile,International, Inc. (OTC Bulletin Board: MDFI), a company specializing ... Practice, a new concierge medical practice,based in Jupiter, Florida, is teaming ...
    ... Medical Students for Community Mental Health Service, ... America Pharmaceutical, Inc., ROCKVILLE, Md., April 1 ... universities as the recipients of Helping,Hands Grants. Each ... community,mental health service project initiated and managed by ...
    ... to Follow Dispute Resolution Process is ... the Most Expeditious Path to Final Approval -, ... DDS;,NASDAQ: DDSS) today announced that it has appealed the ... tramadol formulation to,the next supervisory level under the FDA,s ...
    ... are effective against household ... and pets, health, ATLANTA, April 1 With ... ,green, at home is getting,easier. When it comes to ... because they are not aware that safe and effective,botanical ...
    ... Care and Prevention, WICHITA, Kan., April 1, ... higher new safety standards, including protections,against E. coli, ... farmers and,ranchers behind the food safety seal, "VeriPrime ... Citing growing consumer concern over food safety and ...
    Cached Medicine News:Health News:RxPop.com Announces Partnership with HealthCare.com 2Health News:RxPop.com Announces Partnership with HealthCare.com 3Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 2Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 3Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 4Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 5Health News:Personal Choice Family Practice Empowers Patients With MedeFile Electronic Medical Records Management Solution 6Health News:American Psychiatric Foundation Announces Recipients of 2008 Helping Hands Grants 2Health News:American Psychiatric Foundation Announces Recipients of 2008 Helping Hands Grants 3Health News:American Psychiatric Foundation Announces Recipients of 2008 Helping Hands Grants 4Health News:Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy 2Health News:Labopharm Appeals FDA's Decision on Once-Daily Tramadol to Next Supervisory Level After Additional Analysis Supports Efficacy 3Health News:Safe, 'Green' Insecticides Can Reduce Chemical Exposure in Homes and Gardens 2Health News:Safe, 'Green' Insecticides Can Reduce Chemical Exposure in Homes and Gardens 3Health News:'VeriPrime Certified Safeguards' Food Safety Label Unveiled 2Health News:'VeriPrime Certified Safeguards' Food Safety Label Unveiled 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    Medicine Products: